The melanocortin 2 receptor (MC2R), also known as the adrenocorticotropic hormone (ACTH) receptor, is a G protein-coupled receptor (GPCR) primarily expressed in the adrenal cortex. It plays a critical role in regulating steroidogenesis by binding ACTH, a pituitary-derived hormone, to stimulate cortisol production via the cAMP-PKA signaling pathway. Dysregulation of MC2R is linked to adrenal disorders such as familial glucocorticoid deficiency (FGD) and Cushing’s syndrome, highlighting its importance in endocrine homeostasis.
MC2R antibodies are essential tools for studying receptor expression, localization, and function in adrenal tissues or cell models. They enable detection of MC2R in techniques like Western blot, immunohistochemistry, and immunofluorescence, aiding research on adrenal pathophysiology or drug screening. Some antibodies target extracellular domains to investigate ligand-receptor interactions, while others focus on intracellular regions to study downstream signaling.
Structurally, MC2R requires the melanocortin receptor accessory protein (MRAP) for proper trafficking and ACTH binding—a unique feature among melanocortin receptors. This complexity makes MC2R antibodies valuable for probing receptor-protein interactions and post-translational modifications. Emerging therapeutic strategies, such as MC2R-targeted agonists or antagonists, also rely on antibody-based validation to modulate receptor activity in conditions like adrenal insufficiency or hypercortisolism.